Home>Topics>Stocks>Athersys

Athersys

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
  1. Dropping Coverage of Athersys

    Commentary

    Fri, 13 Jan 2012

    We are no longer providing equity research on Athersys ATHX . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

  2. Athersys Announces Partnership Changes, New Financing Deal

    Commentary

    Mon, 14 Nov 2011

    estimate intact after reviewing Athersys ' ATHX third-quarter results, a business ..... and financing arrangements. Athersys turned in a net loss of $2.3 ..... sheet. To buoy its cash balance, Athersys has entered into an equity purchase

  3. New Morningstar Analyst Report - Athersys Inc.

    Stock Reports

    Thu, 11 Aug 2011

    development of Athersys ' anti-obesity candidate ATHX -105 was put ..... of obesity drug ATHX -105 following ..... clinical risk, Athersys ' MultiStem is ..... company. Although Athersys ' stem cell technology ..... performance of ATHX -105 illustrate

  4. Athersys Under Review as Falling Stock Price Limits Firm's Ability to Raise Capital

    Commentary

    Mon, 8 Aug 2011

    We are putting Athersys ATHX under review in the wake of the company's plummeting share price. Athersys is a development-stage biotech with minimal revenue and negative profits, and equity issuances are key to the firm's survival as it burns

  5. Athersys' MultiStem Shows Activity in Early Stage Trials

    Commentary

    Fri, 22 Jul 2011

    We are maintaining our fair value estimate for Athersys ATHX after reviewing the company's progress over the past ..... MultiStem's assigned probability of approval. In May, Athersys announced positive interim results from an ongoing Phase

  6. MultiStem's Development Pushes Forward, but Much Risk Remains for Athersys

    Commentary

    Wed, 16 Feb 2011

    Athersys ATHX continues to advance its flagship stem-cell ..... unknown about its safety and effectiveness. Athersys has completed enrollment of its Phase ..... and severity of the disease, for which Athersys received orphan drug designation for MultiStem

« Prev12Next »
Content Partners